Syndax Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

06.03.23	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
28.02.23	Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update (PR Newswire)
27.02.23	Ausblick: Syndax Pharmaceuticals informiert über die jüngsten Quartalsergebnisse (finanzen.net)
21.02.23	Syndax to Announce Fourth Quarter and Year-end 2022 Financial Results and Host Conference Call and Webcast on February 28, 2023 (PR Newswire)
14.02.23	Syndax Announces Participation at Upcoming Investor Conferences (PR Newswire)
04.01.23	Syndax Announces Presentation at 41st Annual J.P. Morgan Healthcare Conference (PR Newswire)
14.12.22	Syndax Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
10.12.22	Syndax Announces Positive Updated Data from Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias During Oral Presentations at 64th ASH Annual Meeting (PR Newswire)
08.12.22	Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
07.12.22	Syndax Pharma Prices Public Offering Of About 6.82 Mln Shares At $22.00/shr (RTTNews)
07.12.22	Syndax Announces Pricing of $150 Million Public Offering of Common Stock (PR Newswire)
06.12.22	Syndax Announces Proposed $150 million Public Offering of Common Stock (PR Newswire)
05.12.22	Syndax: FDA Grants Breakthrough Therapy Designation For Revumenib - Quick Facts (RTTNews)
05.12.22	Syndax Announces U.S. FDA Breakthrough Therapy Designation Granted for Revumenib for the Treatment of Adult and Pediatric Patients with Relapsed or Refractory KMT2A- Rearranged (MLLr) Acute Leukemia (PR Newswire)
05.12.22	Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology (PR Newswire)
02.12.22	Syndax Pharma Names Steve Sabus Chief Commercial Officer, Effective Dec. 5 (RTTNews)
02.12.22	Syndax Pharmaceuticals Announces Appointment of Steve Sabus as Chief Commercial Officer (PR Newswire)
21.11.22	Syndax Announces Participation at Evercore ISI Annual HealthCONx Conference (PR Newswire)
03.11.22	Syndax Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Clinical and Business Update (PR Newswire)
03.11.22	Syndax Announces Positive Updates to Clinical Activity and Durable Remissions in Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias (PR Newswire)
02.11.22	Ausblick: Syndax Pharmaceuticals stellt Zahlen zum jüngsten Quartal vor (finanzen.net)
27.10.22	Syndax to Announce Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 3, 2022 (PR Newswire)
07.10.22	These Biotech Stocks Hit New 52-week High, Were They In Your Portfolio? (RTTNews)
08.08.22	Syndax Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Clinical and Business Update (PR Newswire)
07.08.22	Ausblick: Syndax Pharmaceuticals stellt Zahlen zum jüngsten Quartal vor (finanzen.net)
02.08.22	Syndax to Announce Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 8, 2022 (PR Newswire)
16.06.22	Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
13.06.22	Syndax Pharmaceuticals Appoints Keith Goldan As CFO (RTTNews)
13.06.22	Syndax Pharmaceuticals Announces Appointment of Keith A. Goldan as Chief Financial Officer (PR Newswire)
26.05.22	Syndax Announces Participation at Two Upcoming Investor Conferences (PR Newswire)
11.05.22	Syndax Announces Participation at Citi's Biopharma Virtual Co-Panel Day (PR Newswire)
09.05.22	Syndax Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Business Update (PR Newswire)
08.05.22	Ausblick: Syndax Pharmaceuticals zieht Bilanz zum abgelaufenen Quartal (finanzen.net)
02.05.22	Syndax to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 9, 2022 (PR Newswire)
04.03.22	Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
01.03.22	Syndax Pharmaceuticals Reports Fourth Quarter 2021 Financial Results and Provides Clinical and Business Update (PR Newswire)
01.03.22	Syndax Pharmaceuticals Announces Appointment of Kate Madigan, M.D., as Chief Medical Officer (PR Newswire)
28.02.22	Syndax Announces Participation at Two Upcoming Investor Conferences (PR Newswire)
28.02.22	Ausblick: Syndax Pharmaceuticals mit Zahlen zum abgelaufenen Quartal (finanzen.net)
08.02.22	Soligenix to Present at the 2022 BIO CEO & Investor Conference (PR Newswire)
03.02.22	Syndax Pharmaceuticals Announces Transition of Michael A. Metzger to Chief Executive Officer; Briggs W. Morrison, M.D., to Assume Role of President, Head of Research & Development (PR Newswire)
20.01.22	Syndax Announces Presentation at B. Riley Securities' 2022 Oncology Conference (PR Newswire)
07.01.22	Syndax Announces Presentation at 40th Annual J.P. Morgan Healthcare Conference (PR Newswire)
22.12.21	EU Grants Orphan Drug Designation To Syndax's SNDX-5613 For Acute Myeloid Leukemia Treatment (RTTNews)
22.12.21	Syndax Announces Orphan Drug Designation Granted to SNDX-5613 by European Commission for the Treatment of Acute Myeloid Leukemia (PR Newswire)
20.12.21	Syndax Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares (PR Newswire)
16.12.21	Syndax Announces Pricing of $75.3 Million Public Offering (PR Newswire)
15.12.21	Syndax Announces Proposed Public Offering of Common Stock (PR Newswire)
13.12.21	Syndax Pharmaceuticals Announces Additional Positive Data Demonstrating Continued Robust Clinical Activity with Durable Responses in Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613 (PR Newswire)
11.12.21	Syndax Pharmaceuticals Announces Updated Positive Data Demonstrating Broad Activity and Tolerability of Axatilimab in Patients with Chronic Graft-Versus-Host Disease (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Syndax Pharmaceuticals Inc

Aktien Top/Flop

Meistgelesene Nachrichten